{"id":40300,"date":"2013-11-20T12:28:03","date_gmt":"2013-11-20T17:28:03","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=fellowship-training&#038;p=40300"},"modified":"2013-11-20T12:29:04","modified_gmt":"2013-11-20T17:29:04","slug":"aha-13-good-until-the-end","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2013\/11\/20\/aha-13-good-until-the-end\/","title":{"rendered":"AHA.13: Good until the End"},"content":{"rendered":"<p><em>Several Cardiology Fellows who are attending AHA.13 in Dallas this week are blogging for CardioExchange. The Fellows include\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/members\/vimalramjee125\/\">Vimal Ramjee<\/a>,\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/members\/siqinye876\/\">Siqin Ye<\/a>,\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/members\/sethmartin189\/\">Seth Martin<\/a>,\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/members\/revathibalakrishnan378\/\">Reva Balakrishnan<\/a>, and\u00a0\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/members\/sauravchatterjee996\/\">Saurav Chatterjee<\/a>. You can find the previous post\u00a0<a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/fellowship-training\/big-impact-from-a-little-publicized-session-at-aha\/\">here<\/a>. For more of our AHA.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our <\/em><em><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/voices\/aha-13-headquarters\/\">AHA.13 Headquarters<\/a>.<\/em><\/p>\n<p>While the Exhibit Hall was closing down, the poster hall was still buzzing Tuesday afternoon at AHA.13. Here\u2019s what it looked like:<\/p>\n<p style=\"text-align: center;\"><a href=\"http:\/\/blogs.nejm.org\/cardioexchange\/wp-content\/uploads\/sites\/7\/2013\/11\/CXimage.jpeg\"><img decoding=\"async\" class=\" wp-image-40312 aligncenter\" alt=\"CXimage\" src=\"http:\/\/blogs.nejm.org\/cardioexchange\/wp-content\/uploads\/sites\/7\/2013\/11\/CXimage.jpeg\" width=\"100%\" \/><\/a><\/p>\n<p>Did anyone else stop by the side-by-side posters by Peter P. Toth on PCSK9 inhibition? The titles say it all:<\/p>\n<ul>\n<li>Alirocumab, a Proprotein Convertase Subtilisin\/Kexin Type 9 Monoclonal Antibody, Reduces Sterol Concentrations of All Serum Low-Density Lipoprotein Cholesterol Fractions<\/li>\n<li>Alirocumab, a Proprotein Convertase Subtilisin\/Kexin Type 9 Monoclonal Antibody, Reduces Triglycerides and Cholesterol Concentrations of Serum Remnant Lipoprotein Fractions and Very Low-Density Lipoproteins<\/li>\n<\/ul>\n<p>Dr. Toth presented post-hoc analyses using samples from the three alirocumab phase 2 trials in heterozygous FH and non-FH patients. Lipoproteins were subfractionated by Vertical Auto Profile (VAP) testing.The reduction in remnants and VLDL-C by PCSK9 inhibition with alirocumab is both shocking and exciting. Given what we\u2019ve known about the mechanism of action (increasing availability of LDL receptors), we all expected the robust LDL-C reductions, but not the remnant and VLDL-C reduction. How VLDL-C and RLP-C subfractions are been reduced is not yet known; these fascinating results deserve further research to better understand what is going on. To lipidologists, this seems to be a very sexy drug. I am very hopeful that these lipid changes will translate into improved clinical outcomes in the ODYSSEY phase 3 trial program of alirocumab!<\/p>\n<p><i>Are you hopeful about this new approach?<\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>On the last afternoon at AHA.13, a poster on an experimental preventive treatment catches the eye of a cardiology Fellow .<\/p>\n","protected":false},"author":370,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[476,1306,1187,195,533,977],"class_list":["post-40300","post","type-post","status-publish","format-standard","hentry","category-prevention","tag-aha","tag-american-heart-association","tag-cardiology-conferences","tag-fellowship-training-2","tag-ldl-cholesterol","tag-prevention-2"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/40300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/370"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=40300"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/40300\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=40300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=40300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=40300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}